© 2022 MJH Life Sciences and Modern Retina. All rights reserved.
© 2022 MJH Life Sciences™ and Modern Retina. All rights reserved.
October 03, 2022
Those who used both traditional and electronic cigarettes reported severe to very severe ophthalmic symptoms.
October 02, 2022
The AVONELLE-X long-term extension study will continue to evaluate the efficacy, durability, and safety of faricimab in patients with neovascular AMD.
The data analysis showed that the macular thickness decreased across all time periods and in all macular regions for all tertiles.
Janssen noted that results from Phase 1/2 MGT009 study demonstrate safety profile of investigational gene therapy botaretigene sparoparvovec (AAV-RPGR) and suggest sustained vision improvement in patients with X-linked retinitis pigmentosa.
The results also showed that, compared to use of systemic antivirals alone, treatment with adjunctive intravitreal injections or early pars plana vitrectomy did not affect the time to development of retinal detachments.
The data analysis indicated that patients achieved robust visual gains and central subfield thickness reductions with faricimab dosed every 8 weeks and with PTI dosing up to every 16 weeks. The gains were sustained through year 2 of the trials.
October 01, 2022
At AAO 2022, Justis Ehlers, MD, presented a talk entitled, "Defining the Fluid Problem in Neovascular AMD: To Dry or Not to Dry?"
Almost 5 million patients in the IRIS Registry had received at least one diagnosis of DED between 2013 and 2019; of those, 203,171 were children under 18 years of age and 4,592,808 were adults.
September 30, 2022
Investigators reported that the safety and efficacy of the Tecnis Synergy IOL model ZFR00V indicates that it may be a good option for patients who desire meaningful gains in uncorrected visual acuity at all distances.
13% of pediatric patients had new-onset strabismus after a tube shunt procedure; in contrast, 0% of adults had new-onset strabismus after tube shunt surgery (at 6 months or at last follow-up).